Prevalence of Soft Tissue Sarcoma (STS) Subtypes in the US, Risk of Metastases at Diagnosis, and Survival Outcomes
Soft tissue sarcomas (STS) are heterogeneous malignancies with diverse clinical presentations and outcomes.
This study examines the prevalence, metastatic risk, and survival impact of various STS subtypes. By characterizing the disease landscape, we aim to inform treatment strategies, resource allocation, and clinical trial design, ultimately improving patient outcomes.
Click here to download our White paper.
Jump to a slide with the slide dots.
Clinical trial site and sponsor engagement: Ongoing trend impacts & communication strategies.
Clinical trial sponsor and site engagement communication pathways lay the foundation for study performance and data outcomes. In this insight, Blair S
Read more
EMA now needs patient experience data from R&D to access
While patients are valuable contributors across the medicines development lifecycle, patient experience data (PED) are still not systematically includ
Read more
Clinical trial recruitment is not operational, it’s strategic. Let’s stop pretending otherwise.
There is a quiet fiction at the heart of many clinical trials. It goes something like this: “once the protocol is...
Read more
Advancing patient experience data in rare kidney disorder research
Across healthcare, there is increasing recognition that understanding unmet need requires more than traditional clinical and population-level data. St
Read more
Pride in Patient Engagement: Recognizing MedComms Day at MEDiSTRAVA
This year’s MedComms Day theme, Pride in Profession, gives us an opportunity to reflect on the importance of our work in Patient Engagement.
Read more